Translational medicine in action, and validation for the MesenFlow strategy. Mesenchymal factors regulate human CD16 monocyte function in chronic inflammation and cancer. x.com/NatureComms/status/957…
MesenFlow Technologies is proud to be part of a study on circadian rhythms in leukocyte trafficking, published in @ImmunityCP. What a fantastic way to end the year.
We wish our friends and colleagues a Happy New Year for 2019!
cell.com/immunity/pdfExtende…
Commentary on the publication in Nature Comms, with the founders of MesenFlow Technologies. Applying powerful and deliverable translational technologies to cancer therapy. sciencedaily.com/releases/20…
Valdiating a translational approach in the treatment of cancer & chronic inflammation. A radio interview with author Adama Sidibe about a recent publication in Nature Comms. Further validation of the MesenFlow strategy (In French). rts.ch/play/radio/cqfd/audio… via @RadioTeleSuisse